ID: ALA2063324

Max Phase: Preclinical

Molecular Formula: C31H33N5O4

Molecular Weight: 539.64

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(NCc1ccc(-c2cc(NC(=O)c3ccc(OCCN4CCCC4)cc3)[nH]n2)cc1)OCc1ccccc1

Standard InChI:  InChI=1S/C31H33N5O4/c37-30(26-12-14-27(15-13-26)39-19-18-36-16-4-5-17-36)33-29-20-28(34-35-29)25-10-8-23(9-11-25)21-32-31(38)40-22-24-6-2-1-3-7-24/h1-3,6-15,20H,4-5,16-19,21-22H2,(H,32,38)(H2,33,34,35,37)

Standard InChI Key:  MWOBEOJMSDHMFO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 539.64

Molecular Weight (Monoisotopic): 539.2533

AlogP: 5.23

#Rotatable Bonds: 11

Polar Surface Area: 108.58

Molecular Species: BASE

HBA: 6

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.82

CX Basic pKa: 8.81

CX LogP: 5.05

CX LogD: 3.62

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.24

Np Likeness Score: -1.48

References

1. Hsu JT, Yeh TK, Yen SC, Chen CT, Hsieh SY, Hsu T, Lu CT, Chen CH, Chou LH, Chiu CH, Chang YI, Tseng YJ, Yen KR, Chao YS, Lin WH, Jiaang WT..  (2012)  3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).,  22  (14): [PMID:22726931] [10.1016/j.bmcl.2012.05.116]

2. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT..  (2013)  Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).,  21  (11): [PMID:23618709] [10.1016/j.bmc.2013.03.083]

Source

Source(1):

• Scientific Literature